Coherus Returns Rights for Avastin Biosimilar to Innovent
publication date: May 12, 2022
Coherus Biosciences of Redwood City, CA, returned the US rights to market an Innovent Avastin biosimilar to Innovent. Coherus announced the move in its Q1 earnings call with analysts, blaming the COVID-19 epidemic for slowing its development of the biosimilar. Coherus has signed several big deals to market China-developed drugs in North America, a major part of its business plan. However, during the first three months of 2022, it also dissolved a partnership with Junshi Biosciences for an Eylea (aflibercept) biosimilar. More details...
Stock Symbols: (NSDQ: CHRS) (HK:1801) (HK: 1877; SHA: 688180)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.